Advertisement

Topics

Mallinckrodt to buy InfaCare and its paediatric jaundice treatment stannsoporfin

19:00 EDT 6 Aug 2017 | Pharmaceutical Technology

UK-based pharmaceutical company Mallinckrodt has entered an agreement to acquire InfaCare Pharmaceutical and its developmental product, stannsoporfin, used for the treatment of newborns with the risk of developing severe jaundice.

Original Article: Mallinckrodt to buy InfaCare and its paediatric jaundice treatment stannsoporfin

NEXT ARTICLE

More From BioPortfolio on "Mallinckrodt to buy InfaCare and its paediatric jaundice treatment stannsoporfin"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...